Piper Sandler Issues Pessimistic Forecast for Health Catalyst (NASDAQ:HCAT) Stock Price

Health Catalyst (NASDAQ:HCAT) had its target price cut by equities research analysts at Piper Sandler from $12.00 to $8.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Piper Sandler’s price objective points to a potential upside of 47.06% from the stock’s current price.

Several other analysts have also commented on HCAT. Canaccord Genuity Group decreased their price target on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 21st. Wells Fargo & Company decreased their target price on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a research report on Tuesday, January 21st. KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target on the stock in a report on Wednesday, January 8th. Stephens increased their price objective on Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a report on Thursday, November 14th. Finally, Citigroup dropped their target price on Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $10.20.

Health Catalyst Trading Down 1.1 %

Shares of NASDAQ HCAT opened at $5.44 on Tuesday. Health Catalyst has a 1-year low of $5.32 and a 1-year high of $10.14. The business has a fifty day moving average price of $6.69 and a 200 day moving average price of $7.38. The stock has a market capitalization of $331.02 million, a P/E ratio of -4.03 and a beta of 1.34. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41.

Insider Buying and Selling

In other news, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $5.76, for a total value of $30,003.84. Following the transaction, the chief operating officer now directly owns 86,044 shares of the company’s stock, valued at approximately $495,613.44. This represents a 5.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Linda Llewelyn sold 6,442 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $5.80, for a total value of $37,363.60. Following the completion of the transaction, the insider now owns 92,260 shares of the company’s stock, valued at approximately $535,108. The trade was a 6.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 81,169 shares of company stock worth $629,068 in the last 90 days. Insiders own 2.50% of the company’s stock.

Institutional Trading of Health Catalyst

Several institutional investors and hedge funds have recently bought and sold shares of HCAT. ExodusPoint Capital Management LP purchased a new position in shares of Health Catalyst during the fourth quarter worth $107,000. Martin Worley Group acquired a new stake in Health Catalyst during the 4th quarter worth about $78,000. OneAscent Financial Services LLC purchased a new position in shares of Health Catalyst during the 4th quarter valued at about $97,000. Palogic Value Management L.P. acquired a new position in shares of Health Catalyst in the 4th quarter valued at about $2,262,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Health Catalyst in the fourth quarter worth about $216,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.